Strategy and Efficacy of Generic and Pan-genotypic Sofosbuvir/Velpatasvir in Chronic Hepatitis C Virus: A Myanmar Experience.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of clinical and experimental hepatology"
DOI: 10.1016/j.jceh.2018.12.001
Abstract: Background In resource-constrained areas, generic direct-acting antivirals (DAAs) have considerably reduced the cost of hepatitis C virus (HCV) therapy while there remain significant costs related to the baseline and follow-up virologic assays. Aim The aim… read more here.
Keywords: genotype; treatment; pan genotypic; sof vel ... See more keywords
SOF/VEL/VOX Results in High SVR12 Rates when Administered for 12 Weeks in Daa-Experienced Patients or for 8 Weeks in Daa-Naïve Patients: An Integrated Analysis of the POLARIS-1, POLARIS-2, POLARIS-3 and POLARIS-4 Studies
Sign Up to like & getrecommendations! Published in 2017 at "Gastroenterology"
DOI: 10.1016/s0016-5085(17)33572-2
Abstract: Background The once-daily fixed-dose combination tablet of sofosbuvir/velpatasvir/voxilaprevir(SOF/VEL/VOX) was evaluated for the treatment of genotype 1–6 HCV infection in four Phase 3 studies in direct-acting antiviral (DAA)-experienced (POLARIS-1 and POLARIS-4) and DAA-naive (POLARIS-2 and POLARIS-3)… read more here.
Keywords: polaris polaris; sof vel; weeks daa; polaris ... See more keywords
Efficacy and safety of the sofosbuvir/velpatasvir combination for the treatment of patients with early mild to moderate COVID-19
Sign Up to like & getrecommendations! Published in 2022 at "Scientific Reports"
DOI: 10.1038/s41598-022-09741-5
Abstract: SARS-CoV-2 is still a health problem worldwide despite the availability of vaccines. Therefore, there is a need for effective and safe antiviral. SARS-CoV-2 and HCV necessitate RNA-dependent RNA polymerase (RdRp) for replication; therefore, it has… read more here.
Keywords: sof vel; treatment; moderate covid; mild moderate ... See more keywords
Real‐world effectiveness of sofosbuvir/velpatasvir/voxilaprevir in 573 direct‐acting antiviral experienced hepatitis C patients
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Viral Hepatitis"
DOI: 10.1111/jvh.13115
Abstract: Sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) provides a needed hepatitis C virus (HCV) antiviral option for direct‐acting antiviral (DAA)‐experienced patients. We evaluated the effectiveness of SOF/VEL/VOX for 12 weeks in DAA‐experienced patients with genotype 1‐4 treated in clinical practice.… read more here.
Keywords: sof vel; vel vox; svr rates;
Real world SOF/VEL/VOX retreatment outcomes and viral resistance analysis for HCV patients with prior failure to DAA therapy
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Viral Hepatitis"
DOI: 10.1111/jvh.13549
Abstract: Sustained viral response (SVR) rates for direct‐acting antiviral (DAA) therapy for hepatitis C virus (HCV) infection routinely exceed 95%. However, a small number of patients require retreatment. Sofosbuvir, velpatasvir and voxilaprevir (SOF/VEL/VOX) is a potent… read more here.
Keywords: vel; retreatment; sof vel; daa ... See more keywords
The tolerability of sofosbuvir/velpatasvir for 12 weeks in patients treated in the ASTRAL 1, 2 and 3 studies: A pooled safety analysis
Sign Up to like & getrecommendations! Published in 2023 at "Journal of Viral Hepatitis"
DOI: 10.1111/jvh.13814
Abstract: To evaluate the safety and tolerability of the fixed‐dose, single‐tablet regimen sofosbuvir/velpatasvir (SOF/VEL) for the treatment of hepatitis C virus (HCV) infection in three Phase 3 studies in patients with and without compensated cirrhosis. Data… read more here.
Keywords: safety; sof vel; tolerability; patients treated ... See more keywords
Italian Real-World Analysis of the Impact of Polypharmacy and Aging on the Risk of Multiple Drug–Drug Interactions (DDIs) in HCV Patients Treated with Pangenotypic Direct-Acting Antivirals (pDAA)
Sign Up to like & getrecommendations! Published in 2022 at "Therapeutics and Clinical Risk Management"
DOI: 10.2147/tcrm.s394467
Abstract: Purpose The study aims at investigating the impact of polymedication and aging in the prevalence of multiple drug-drug interactions (DDIs) on HCV patients treated with sofosbuvir/velpatasvir (SOF/VEL) or glecaprevir/pibrentasvir (GLE/PIB). Patients and Methods This is… read more here.
Keywords: sof vel; drug; gle pib;
Cost-Effectiveness Analysis of Pan-Genotypic Sofosbuvir-Based Regimens for Treatment of Chronic Hepatitis C Genotype 1 Infection in China
Sign Up to like & getrecommendations! Published in 2021 at "Frontiers in Public Health"
DOI: 10.3389/fpubh.2021.779215
Abstract: Background: Hepatitis C virus (HCV) genotype 1 is the most prevalent HCV infection in China. Sofosbuvir-based direct antiviral agent (DAA) regimens are the current mainstays of treatment. Sofosbuvir/velpatasvir (SOF/VEL) and sofosbuvir/ledipasvir (SOF/LDV) regimens became reimbursable… read more here.
Keywords: sof vel; genotype; sof; cost ... See more keywords
Efficacy and safety of sofosbuvir/velpatasvir with or without ribavirin in hepatitis C genotype 3 compensated cirrhosis: A meta-analysis
Sign Up to like & getrecommendations! Published in 2022 at "World Journal of Hepatology"
DOI: 10.4254/wjh.v14.i6.1248
Abstract: BACKGROUND Hepatitis C virus (HCV) is a leading cause of liver cirrhosis and hepatocellular carcinoma globally. Sofosbuvir/velpatasvir (SOF/VEL) is an effective pan-genotypic direct-acting antiviral combination for treatment of chronic HCV infection. While the addition of… read more here.
Keywords: compensated cirrhosis; sof vel; gt3 compensated; cirrhosis patients ... See more keywords